NASDAQ:AXSM - Axsome Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $130.86
  • Forecasted Upside: 85.59 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.83 (1.19%)

This chart shows the closing price for AXSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

Analyst Price Target is $130.86
▲ +85.59% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $130.86, with a high forecast of $225.00 and a low forecast of $66.00. The average price target represents a 85.59% upside from the last price of $70.51.

This chart shows the closing price for AXSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Axsome Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021Berenberg BankInitiated CoverageBuy$112.00High
5/26/2021Morgan StanleyBoost Price TargetOverweight$104.00 ➝ $105.00Medium
5/12/2021BTIG ResearchReiterated RatingBuyLow
4/27/2021HC WainwrightBoost Price TargetBuy$210.00 ➝ $225.00High
3/2/2021MizuhoLower Price TargetBuy$120.00 ➝ $118.00Low
3/2/2021Morgan StanleyBoost Price TargetOverweight$101.00 ➝ $104.00Low
1/8/2021Jefferies Financial GroupInitiated CoverageBuy$129.00Low
12/31/2020UBS GroupReiterated RatingPositiveN/A
12/15/2020MizuhoInitiated CoverageBuy$120.00Low
12/3/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$131.00 ➝ $161.00High
11/9/2020Morgan StanleyLower Price TargetOverweight$102.00 ➝ $101.00Low
10/1/2020William BlairReiterated RatingBuyLow
9/29/2020Bank of AmericaInitiated CoverageUnderperform$66.00High
9/10/2020Morgan StanleyInitiated CoverageOverweight$102.00Low
9/4/2020William BlairReiterated RatingBuyN/A
8/21/2020William BlairReiterated RatingBuyLow
8/10/2020William BlairReiterated RatingBuyMedium
8/6/2020HC WainwrightReiterated RatingBuy$210.00Low
7/14/2020HC WainwrightReiterated RatingBuy$210.00Medium
6/30/2020HC WainwrightReiterated RatingBuy$210.00High
4/28/2020GuggenheimBoost Price TargetIn-Line ➝ Buy$158.00 ➝ $200.00Medium
4/28/2020HC WainwrightBoost Price TargetBuy$200.00 ➝ $210.00Medium
4/27/2020Cantor FitzgeraldBoost Price TargetOverweight$125.00 ➝ $131.00Low
4/27/2020LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$165.00 ➝ $186.00Low
4/27/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$145.00 ➝ $200.00High
4/14/2020CowenInitiated CoverageOutperform$95.00High
4/6/2020William BlairReiterated RatingBuyHigh
4/6/2020HC WainwrightReiterated RatingBuy$200.00High
3/16/2020HC WainwrightReiterated RatingBuy$200.00High
2/24/2020HC WainwrightReiterated RatingBuy$200.00Low
1/28/2020HC WainwrightReiterated RatingBuy$200.00High
1/21/2020HC WainwrightReiterated RatingBuyMedium
1/14/2020LADENBURG THALM/SH SHReiterated RatingBuy$139.00 ➝ $165.00Medium
1/2/2020SunTrust BanksBoost Price TargetBuy$140.00Medium
12/30/2019BTIG ResearchBoost Price TargetBuy$97.00Medium
12/30/2019LADENBURG THALM/SH SHBoost Price TargetBuy$139.00 ➝ $165.00Low
12/30/2019Cantor FitzgeraldReiterated RatingOverweight$104.00 ➝ $125.00Medium
12/24/2019HC WainwrightReiterated RatingBuy$170.00 ➝ $200.00Medium
12/17/2019SunTrust BanksBoost Price TargetBuy$100.00High
12/17/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$97.00High
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$125.00Medium
12/16/2019Cantor FitzgeraldBoost Price TargetOverweight$55.00 ➝ $104.00High
12/4/2019GuggenheimBoost Price Target$65.00 ➝ $48.00High
12/4/2019SunTrust BanksReiterated RatingBuy ➝ Positive$60.00High
12/4/2019BTIG ResearchReiterated RatingBuy ➝ Positive$48.00Medium
12/3/2019Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$45.00 ➝ $55.00High
11/26/2019Cantor FitzgeraldReiterated RatingBuy$45.00High
10/17/2019HC WainwrightReiterated RatingBuy$30.00High
10/16/2019GuggenheimInitiated CoverageBuy$48.00High
9/18/2019William BlairInitiated CoverageOutperform$48.00Low
6/24/2019HC WainwrightSet Price TargetBuy$30.00Low
5/28/2019Cantor FitzgeraldReiterated RatingOverweight$25.00 ➝ $35.00Low
5/28/2019SunTrust BanksInitiated CoverageBuy ➝ BuyLow
5/23/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $30.00High
4/15/2019HC WainwrightReiterated RatingBuy ➝ Average$18.00 ➝ $23.00High
4/8/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Medium
3/28/2019BTIG ResearchBoost Price TargetBuy$25.00Low
3/26/2019HC WainwrightSet Price TargetBuy$18.00High
3/21/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $25.00High
3/15/2019HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $18.00High
3/15/2019Cantor FitzgeraldBoost Price TargetOverweight$13.00 ➝ $16.00High
3/5/2019HC WainwrightSet Price TargetBuy$15.00High
1/31/2019HC WainwrightReiterated RatingBuy$15.00Low
1/14/2019HC WainwrightReiterated RatingBuy$15.00Low
1/8/2019BTIG ResearchBoost Price TargetBuy$20.00High
1/7/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$34.00 ➝ $45.00High
1/7/2019HC WainwrightBoost Price TargetBuy$15.00High
12/10/2018Cantor FitzgeraldSet Price TargetBuy$16.00High
12/5/2018HC WainwrightReiterated RatingBuy$10.00High
11/15/2018Cantor FitzgeraldInitiated CoverageOverweight$16.00High
10/24/2018HC WainwrightSet Price TargetBuy$10.00Low
10/17/2018LADENBURG THALM/SH SHSet Price TargetBuy$34.00 ➝ $5.00High
10/9/2018HC WainwrightSet Price TargetBuy$10.00High
8/21/2018HC WainwrightReiterated RatingBuy$10.00Low
6/7/2018HC WainwrightInitiated CoverageBuy$10.00High
4/29/2018BTIG ResearchReiterated RatingBuy$16.00High
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
7/26/2017LADENBURG THALM/SH SHReiterated RatingBuy$28.00 ➝ $31.00High
6/20/2017AegisReiterated RatingBuy$20.00High
5/25/2017AegisReiterated RatingBuy$20.00Medium
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00High
3/21/2017AegisReiterated RatingBuyHigh
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
2/14/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
1/11/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
1/3/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
11/15/2016Cantor FitzgeraldReiterated RatingBuy$13.00N/A
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/A
8/21/2016Brean CapitalSet Price TargetBuy$29.00N/A
8/10/2016Cantor FitzgeraldSet Price TargetBuy$13.00N/A
8/10/2016Brean CapitalReiterated RatingBuyN/A
(Data available from 6/24/2016 forward)
Axsome Therapeutics logo
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Read More

Today's Range

Now: $70.51
Low: $69.40
High: $71.32

50 Day Range

MA: $59.95
Low: $50.63
High: $71.16

52 Week Range

Now: $70.51
Low: $50.05
High: $90.00


289,456 shs

Average Volume

343,037 shs

Market Capitalization

$2.65 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?

The following Wall Street analysts have issued reports on Axsome Therapeutics in the last year: Bank of America Co., Berenberg Bank, BTIG Research, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, UBS Group AG, and William Blair.
View the latest analyst ratings for AXSM.

What is the current price target for Axsome Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Axsome Therapeutics in the last year. Their average twelve-month price target is $130.86, suggesting a possible upside of 85.6%. HC Wainwright has the highest price target set, predicting AXSM will reach $225.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $66.00 for Axsome Therapeutics in the next year.
View the latest price targets for AXSM.

What is the current consensus analyst rating for Axsome Therapeutics?

Axsome Therapeutics currently has 1 sell rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXSM will outperform the market and that investors should add to their positions of Axsome Therapeutics.
View the latest ratings for AXSM.

What other companies compete with Axsome Therapeutics?

How do I contact Axsome Therapeutics' investor relations team?

Axsome Therapeutics' physical mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company's listed phone number is 212-332-3241. The official website for Axsome Therapeutics is